In an era where the biopharmaceutical landscape is defined by the dual pressures of rapid clinical innovation and the need for massive, reliable manufacturing scale, FUJIFILM Biotechnologies (FUJIFILM Diosynth Biotechnologies) has emerged as a titan of industrial infrastructure. With a staggering $7 billion in capital expansion projects currently underway across North America and Europe, the contract development and manufacturing organization (CDMO) is not merely adding capacity—it is architecting a globally integrated, AI-augmented ecosystem.
At the helm of this operational evolution is Maja Herold Pedersen, who transitioned from Chief Quality Officer to Chief Technology Officer, and subsequently to Chief Operating Officer in September 2025. Her leadership represents a departure from traditional "siloed" pharma management, prioritizing a unified vision that collapses the distance between quality assurance and operational agility.
The Scale of Ambition: A Global Infrastructure Buildout
FUJIFILM’s current growth strategy is arguably one of the most aggressive in the history of the life sciences sector. The company is actively building a redundant, high-capacity network designed to offer pharmaceutical sponsors a seamless transition from laboratory-scale development to commercial-scale manufacturing.
The North American Pillar
The cornerstone of this strategy is the $3.2 billion facility in Holly Springs, North Carolina. Launched in September 2025, the site represents a major leap in commercial-scale cell culture manufacturing. With a second phase of expansion already penciled in for 2028, the site is designed to accommodate the next decade of therapeutic demand. Simultaneously, the sister subsidiary, FUJIFILM Cellular Dynamics, has bolstered its footprint with a new $200 million iPSC (induced pluripotent stem cell) manufacturing headquarters in Madison, Wisconsin, aimed at quadrupling the company’s cell-production capacity.
European and UK Advancements
Across the Atlantic, the company is fortifying its Danish Hillerød campus. The expansion includes the integration of eight additional 20,000-liter bioreactors and two new downstream processing streams, ensuring the site remains one of the world’s most significant hubs for biologic drug substance production. In the United Kingdom, the Teesside facility—which opened in early 2026—has secured its status as the nation’s largest single-use CDMO site, further diversifying the company’s technology portfolio to handle both traditional stainless-steel and modern single-use requirements.
The "kojoX" Model: Standardizing the Global Network
The central challenge for any global CDMO is the "tech transfer" bottleneck—the often-arduous process of moving a validated process from one site to another. FUJIFILM has addressed this through the introduction of kojoX, a modular bioproduction philosophy.
Derived from the Japanese word kojo (meaning both "factory" and "improvement") and the "X" of exponential scaling, the system functions as a standardized blueprint. By synchronizing equipment, digital process controls, and quality systems across all global sites, FUJIFILM allows sponsors to transfer a drug-substance process to any equivalent line within the network. This standardization is designed to compress regulatory timelines, significantly reducing the "risk of transition" that often plagues drug developers as they move toward late-stage clinical trials and commercial launch.
Bridging Quality and Operations: The Pedersen Philosophy
Maja Herold Pedersen’s rise to COO is reflective of a broader shift in the life sciences industry: the recognition that quality cannot be a "check-the-box" function performed after the fact. It must be baked into the operational DNA.
"I’ve never been a quality-function-only leader," Pedersen notes. "I’ve always looked at the whole picture of how we get medicine to patients. Whether I’m wearing a quality hat or an operations hat, the goal remains the same: the patient."
Pedersen’s early career began in regulatory and quality roles, where she gained exposure to patient advocacy groups. This early, direct engagement with the end-users of life-saving therapies informs her leadership today. She argues that the bureaucratic tendencies of the pharmaceutical industry—often justified by the need for regulatory compliance—can inadvertently become the greatest barrier to speed. Her leadership strategy, therefore, is focused on creating a culture of "empowered accountability."
AI in the Trenches: Beyond the Pilot Phase
While many pharmaceutical organizations view Artificial Intelligence as a tool for R&D, Pedersen is pushing for its integration into the "dirty work" of GMP (Good Manufacturing Practice) operations.
The Birth of "GenkiBot"
Recognizing that staff would naturally turn to external, non-secure AI tools like ChatGPT if denied internal options, Pedersen spearheaded the development of "GenkiBot." Named after the Japanese term for enthusiasm and positivity, GenkiBot is a secure, internally hosted large language model (LLM) environment.
"If we don’t build it, people will use the other ones anyway," Pedersen explains. "By building it under our own security umbrella, we ensure that intellectual property and patient data remain protected."
The tool is already being deployed for high-value tasks, such as:
- Automated Deviation Management: GenkiBot helps subject matter experts (SMEs) draft deviation reports, coaching them on compliance standards and assisting in more rigorous root-cause analysis that moves beyond repetitive, superficial conclusions.
- Tech Transfer Acceleration: The company is currently exploring ways to use AI to ingest, organize, and format the massive volumes of data required for tech transfers, transforming a labor-intensive, manual process into a semi-automated workflow.
Scaling and the "Agentic" Future
Pedersen’s vision for AI is inherently "agentic." Rather than boxing AI into rigid, narrow use cases, she advocates for a decentralized approach. "To scale the use of AI, we need to equip everyone with the ability to do that kind of coding," she suggests. By encouraging a broader, bottom-up adoption of AI agents—akin to the ubiquity of Excel macros in the early 2000s—she believes the company can create a "funnel" of innovation. Verified, high-performing agents can then be transitioned into the more strictly controlled, GMP-critical environment, ensuring that the most effective tools rise to the top.
Cultivating Culture: The 9 People Fundamentals
Technical infrastructure and AI are insufficient without the human element. Pedersen oversees the implementation of the "9 People Fundamentals," a framework designed to replace rigid hierarchical decision-making with distributed empowerment.
"We want to set people free to make the decisions that each individual is best placed to make," she says. "Biopharma is becoming so complex that we can no longer wait for these tedious decision paths."
This cultural shift is currently supported by a "Leaders for Life" program, which forces senior managers to confront their own decision-making styles and reactions. It is a philosophy that requires a high degree of maturity; empowerment, as Pedersen points out, is not the same as freedom from responsibility. It is a dual-edged sword that demands extreme accountability from every employee, regardless of their position in the organizational chart.
Implications: The Future of CDMOs
The path FUJIFILM is carving out suggests a significant shift in the CDMO value proposition. The traditional model, based on providing raw capacity (bioreactors and stainless steel), is becoming commoditized. The future of the industry lies in integrated intelligence.
By combining physical scale (the $7 billion buildout) with digital agility (GenkiBot and kojoX) and a culture of decentralized empowerment, FUJIFILM is positioning itself as a "partner in the process" rather than a mere vendor.
For the pharmaceutical industry, the implications are profound. If the industry can successfully navigate the regulatory hurdles of AI integration—maintaining the "human-in-the-loop" requirement while accelerating technical processes—the time-to-market for complex biologics could shrink dramatically.
As Pedersen concludes, the goal is to make the complex appear simple. "We’re making things difficult for people in order to make the freedom possible," she reflects. "Being empowered doesn’t come for free. But it is an amazing place to be, and that is how we will eventually deliver better outcomes for the patients who need them most."
About the Author
